1.南京中医药大学附属南京中医院,江苏省南京市秦淮区大明路157号,210001
2.江苏省丹阳市中医院
huizhen68@sohu.com
收稿:2025-05-10,
修回:2025-07-02,
纸质出版:2025-10-02
移动端阅览
周子钦,戴隆华,符加荣等.复方通络饮治疗皮质下缺血性血管性轻度认知障碍肝肾亏虚、痰瘀阻络证的随机对照试验[J].中医杂志,2025,66(19):2023-2029.
ZHOU Ziqin,DAI Longhua,FU Jiarong,et al.Compound Tongluo Decoction(复方通络饮)in Treating Subcortical Ischemic Vascular Mild Cognitive Impairment with Liver-Kidney Deficiency and Phlegm-Stasis Obstructing Collateral Syndrome: A Randomized Controlled Trial[J].Journal of Traditional Chinese Medicine,2025,66(19):2023-2029.
周子钦,戴隆华,符加荣等.复方通络饮治疗皮质下缺血性血管性轻度认知障碍肝肾亏虚、痰瘀阻络证的随机对照试验[J].中医杂志,2025,66(19):2023-2029. DOI: 10.13288/j.11-2166/r.2025.19.010.
ZHOU Ziqin,DAI Longhua,FU Jiarong,et al.Compound Tongluo Decoction(复方通络饮)in Treating Subcortical Ischemic Vascular Mild Cognitive Impairment with Liver-Kidney Deficiency and Phlegm-Stasis Obstructing Collateral Syndrome: A Randomized Controlled Trial[J].Journal of Traditional Chinese Medicine,2025,66(19):2023-2029. DOI: 10.13288/j.11-2166/r.2025.19.010.
目的
2
观察复方通络饮治疗皮质下缺血性血管性轻度认知障碍(SIVD-MCI)肝肾亏虚、痰瘀阻络证患者的临床疗效,并探讨相关作用机制。
方法
2
采用随机、平行、对照的临床试验方法,纳入110例SIVD-MCI肝肾亏虚、痰瘀阻络证患者,随机分为治疗组和对照组各55例,两组均给予基础治疗,对照组再给予口服尼莫地平片,每次30 mg,每日3次;治疗组再给予复方通络饮口服,每日1剂,早晚温服。两组均治疗12周。治疗前后比较蒙特利尔认知评估量表(MoCA)评分、简易精神状态检查量表(MMSE)评分、中医证候评分,治疗前后检测患者血清神经血管营养因子[血管内皮生长因子(VEGF)、脑源性神经营养因子(BDNF)、胰岛素样生长因子1(IGF-1)]水平,以及血清氧化应激相关指标[丙二醛(MDA)、活性氧(ROS)、超氧化物歧化酶(SOD)]水平,并于治疗前后检测血常规、肝功能、肾功能指标,记录试验期间不良反应的发生情况以判定安全性。
结果
2
最终完成试验患者共93例,其中治疗组47例,对照组46例。与本组治疗前比较,两组患者治疗后MoCA、MMSE评分和血清VEGF、BDNF、IGF-1、SOD水平均提高(
P
<0.05),中医证候总评分和血清MDA、ROS水平均降低(
P
<0.05)。与对照组治疗后比较,治疗组治疗后MoCA、MMSE评分和血清VEGF、BDNF、IGF-1、SOD水平均提高,中医证候总评分和血清MDA、ROS水平均降低(
P
<0.05)。治疗期间两组患者均未出现严重肝肾功能损害或死亡等不良结局,实验室检测结果未见与试验药物相关且具有临床意义的变化。
结论
2
复方通络饮可能通过提高SIVD-MCI肝肾亏虚、痰瘀阻络证患者神经血管营养因子水平、抑制氧化应激反应,从而发挥提高患者认知功能、改善临床症状的作用。
Objective
2
To explore the clinical effectiveness and potential mechanisms of
Compound Tongluo Decoction
(复方通络饮) in
treating patients diagnosed with subcortical ischemic vascular mild cognitive impairment (SIVD-MCI) with liver-kidney deficiency and phlegm-stasis obstructing collateral syndrome.
Methods
2
We conducted a randomized, parallel-controlled clinical trial involving 110 eligible SIVD-MCI patients with liver-kidney deficiency and phlegm-stasis obstructing collateral syndrome. Participants were randomly assigned to either treatment group (n=55) or control group (n=55). Both groups received basic treatment. The control group additionally received oral nimodipine tablets at 30 mg for three times daily, and the treatment group additionally received
Compound Tongluo Decoction
orally, one dose daily, taken in the morning and evening. Both groups underwent treatment for 12 weeks. Montreal Cognitive Assessment (MoCA) scores, Mini-Mental State Examination (MMSE) scores, traditional Chinese medicine (TCM) syndrome scores, alterations in serum neurovascular nutrient factors including vascular endothelial growth factor (VEGF), brain-derived neurotrophic factor (BDNF), insulin-like growth factor-1 (IGF-1), and serum oxidative stress-related markers shcu as malondialdehyde (MDA), reactive oxygen species (ROS), and superoxide dismutase (SOD) were compared before and after treatment; blood tests, liver/kidney function tests were also conducted at baseline and post-treatment; adverse reactions occurring during the trial were recorded to evaluate safety.
Results
2
A total of 93 patients completed the trial, including 47 in the treatment group and 46 in the control group. Compared with levels within the group, both groups showed significant increases in MoCA and MMSE scores, as well as serum VEGF, BDNF, IGF-1, and SOD levels after treatment (
P
<0.05), and significant decreases in total TCM syndrome scores and serum MDA and ROS levels (
P
<0.05). Compared with the control group after treatment, the treatment group showed increased MoC
A and MMSE scores, as well as elevated serum VEGF, BDNF, IGF-1, and SOD levels, and decreased TCM syndrome score and serum MDA and ROS levels (
P
<0.05). No adverse outcomes such as severe hepatic or renal dysfunction or mortality occurred in either group during treatment. Laboratory test showed no clinically significant changes related to the study medication.
Conclusion
2
Compound Tongluo Decoction
may exert its effects in enhancing cognitive function and alleviating clinical symptoms by elevating neurotrophic factor levels and suppressing oxidative stress in SIVD-MCI patients with liver-kidney deficiency and phlegm-stasis obstructing collateral syndrome.
中华医学会老年医学分会老年神经病学组 , 脑小血管病认知功能障碍诊疗指南中国撰写专家组 . 脑小血管病相关认知功能障碍中国诊疗指南(2019) [J]. 中华老年医学杂志 , 2019 , 38 ( 4 ): 345 - 354 .
PANTONI L . Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges [J]. Lancet Neurol , 2010 , 9 ( 7 ): 689 - 701 .
魏文石 , 宿映 . 脑小血管病与认知功能障碍 [J]. 重庆医科大学学报 , 2017 , 42 ( 6 ): 643 - 647 .
蔡颖颖 , 蒋卫民 . 中医药干预血管性认知障碍的研究进展 [J]. 中国中药杂志 , 2017 , 42 ( 10 ): 1837 - 1841 .
周仲瑛 , 周学平 . 中医病机辨证学 [M]. 北京 : 中国中医药出版社 , 2013 : 99 - 228 .
惠振 , 张臻年 , 张敬华 , 等 . 复方通络饮对脑梗死急性期患者神经功能及血管生长相关因子的影响 [J]. 中医杂志 , 2018 , 59 ( 16 ): 1383 - 1385,1390 .
LI P , WANG Z , ZHAO T , et al . Protective effect of compound Tongluo decoction on brain vascular endothelial cells after ischemia-reperfusion by inhibition of ferroptosis through regulating Nrf2/ARE/SLC7A11 signaling pathway [J]. Adv Biol (Weinh) , 2024 , 8 ( 3 ): e2300416 .
惠振 , 张敬华 , 石美玲 , 等 . 复方通络饮对脑梗死大鼠的神经保护作用及其促血管新生机制研究 [J]. 中西医结合心脑血管病杂志 , 2018 , 16 ( 2 ): 153 - 158 .
FAZEKAS F , CHAWLUK JB , ALAVI A , et al . MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging [J]. AJR Am J Roentgenol , 1987 , 149 ( 2 ): 351 - 356 .
MORRIS JC . The Clinical Dementia Rating (CDR): current version and scoring rules [J]. Neurology , 1993 , 43 ( 11 ): 2412 - 2414 .
FOLSTEIN MF , FOLSTEIN SE , MCHUGH PR . " Mini-mental state". A practical method for grading the cognitive state of patients for the clinician [J] . J Psychiatr Res , 1975 , 12 ( 3 ): 189 - 198 .
张明园 , 何燕玲 . 精神科评定量表手册 [M]. 长沙 : 湖南科学技术出版社 , 2015 : 313 - 315 .
国家药品监督管理局药品审评中心 . 证候类中药新药临床研究技术指导原则 [EB/OL]. ( 2018-11-04 )[ 2025-05-31 ]. https://www.cde.org.cn/zdyz/domesti-cinfopage? zdyzIdCODE=b43cc2e63b3a79d587347223d41dd7db https://www.cde.org.cn/zdyz/domesti-cinfopage?zdyzIdCODE=b43cc2e63b3a79d587347223d41dd7db .
田金州 , 韩明向 , 涂晋文 , 等 . 血管性痴呆诊断、辨证及疗效评定标准(研究用) [J]. 中国老年学杂志 , 2002 , 22 ( 5 ): 329 - 331 .
ZHENG H , WANG Y , WANG A , et al . The efficacy and safety of nimodipine in acute ischemic stroke patients with mild cognitive impairment: a double-blind, rando-mized, placebo-controlled trial [J]. Sci Bull (Beijing) , 2019 , 64 ( 2 ): 101 - 107 .
NASREDDINE ZS , PHILLIPS NA , BÉDIRIAN V , et al . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment [J]. J Am Geriatr Soc , 2005 , 53 ( 4 ): 695 - 699 .
LACHIN JM . Introduction to sample size determination and power analysis for clinical trials [J]. Control Clin Trials , 1981 , 2 ( 2 ): 93 - 113 .
国家药品监督管理局 , 国家卫生健康委 . 国家药监局 国家卫生健康委关于发布药物临床试验质量管理规范的公告 [EB/OL].( 2020-04-23 )[ 2025-06-30 ]. https: //www.gov.cn/zhengce/zhengceku/2020-04/28/content_5507145.htm https://www.gov.cn/zhengce/zhengceku/2020-04/28/content_5507145.htm .
郭会映 , 孙芳 , 张宗军 , 等 . 皮质下缺血性血管性认知功能障碍的静息态功能磁共振研究 [J]. 中华老年心脑血管病杂志 , 2013 , 15 ( 12 ): 1257 - 1260 .
刘宇蕾 , 杨志奇 , 尹榕 . 氧化应激在脑小血管病认知障碍中的作用机制 [J]. 神经解剖学杂志 , 2024 , 40 ( 3 ): 391 - 394 .
肖俊杰 , 成燕 , 詹青 . 慢性脑缺血导致认知障碍的病理生理学机制 [J]. 国际脑血管病杂志 , 2009 , 17 ( 8 ): 614 - 617 .
QARNI T , SALARDINI A . A multifactor approach to mild cognitive impairment [J]. Semin Neurol , 2019 , 39 ( 2 ): 179 - 187 .
师千与 , 程全成 , 陈春花 . 缺血性脑卒中与血管性痴呆在发病机制上的联系 [J]. 解剖学报 , 2021 , 52 ( 5 ): 834 - 838 .
ZHU Y , LEE C , SHEN F , et al . Angiopoietin-2 facilitates vascular endothelial growth factor-induced angioge-nesis in the mature mouse brain [J]. Stroke , 2005 , 36 ( 7 ): 1533 - 1537 .
NAGAHARA AH , TUSZYNSKI MH . Potential therapeutic uses of BDNF in neurological and psychiatric disorders [J]. Nat Rev Drug Discov , 2011 , 10 ( 3 ): 209 - 219 .
WESTWOOD AJ , BEISER A , DECARLI C , et al . Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy [J]. Neurology , 2014 , 82 ( 18 ): 1613 - 1619 .
MOORHOUSE P , ROCKWOOD K . Vascular cognitive impairment:current concepts and clinical developments [J]. Lancet Neurol , 2008 , 7 ( 3 ): 246 - 255 .
WARDLAW JM , SMITH C , DICHGANS M . Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging [J]. Lancet Neurol , 2013 , 12 ( 5 ): 483 - 497 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号